source
- Pfizer and Amgen target GLP-1 weight-loss market to rival Novo Nordisk and Eli LillyThe STATus Report video hosted by Alex Hogan discusses the growing GLP-1 weight-loss drug market. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years and are pop…
- Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines. Today the conversation has shifted toward the commercial possibilit…